Intellia Hit With Patent Suit on $100 Million Regeneron R&D Deal

Intellia Therapeutics Inc. infringes three BlueAllele Corp. patents related to technology for inserting healthy DNA into genes to enhance genetic-disease treatments, including through Intellia’s $100 million collaboration with Regeneron Pharmaceuticals Inc., according to a lawsuit in Delaware federal court.

Minnesota-based BlueAllele alleges that Intellia’s “experimenting, basic research, identification, optimizing, manufacturing, using, and making of bi-directional insertion templates” infringes US Patent Nos. 11,091,756; 11,254,930; and 11,365,407, according to a complaint filed Monday in the US District Court for the District of Delaware. Intellia didn’t immediately respond to a request for comment.

• BlueAllele alleges Intellia has used the ...